Physician profile
Mary Brady
NPI 1922486695
$1,230.05
in general payments reported to CMS, 2019-2025
14 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.56 · 2022: $196 · 2023: $125 · 2024: $413 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $348.74 | 2022-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $278.04 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $113.22 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $111.06 | 2024-2025 | |
| Genentech USA, INC. | $79.56 | 2019 | |
| Organogenesis INC. | $61.00 | 2024-2025 | Via Matrix, Cygnus Dual |
| Regeneron Healthcare Solutions, INC. | $50.38 | 2025 | Dupixent |
| Biowound Solutions, INC. | $37.75 | 2025 | Bio-Connekt |
| Incyte Corporation | $34.82 | 2024 | Opzelura |
| Ucb, INC. | $29.88 | 2025 | Bimzelx |
| Convatec INC. | $24.17 | 2024 | |
| Janssen Biotech, INC. | $23.57 | 2025 | Tremfya |
| Amgen INC. | $22.83 | 2025 | Otezla |
| Journey Medical Corporation | $15.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.